Medtrade Products develops medical device products with a strong track record in the advanced woundcare and haemostat markets. The company highlights in-house development expertise, a rapid product development process, and long-standing relationships with global blue-chip companies. Medtrade leverages industry-leading Celox haemostat technology and is positioned to expand that offering. The business reports strong profitability and a cash-generation profile. Management intends to accelerate product development and pursue global expansion to grow within the $9.8bn advanced woundcare market. Medtrade was founded in 1999 and is based in Crewe, United Kingdom.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

May 2019